Acrivon Therapeutics (Acrivon Therapeutics) Book Value per Share : $4.77 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Acrivon Therapeutics Book Value per Share?

Acrivon Therapeutics's book value per share for the quarter that ended in Mar. 2024 was $4.77.

During the past 12 months, Acrivon Therapeutics's average Book Value Per Share Growth Rate was -34.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Acrivon Therapeutics's current price is $7.28. Its book value per share for the quarter that ended in Mar. 2024 was $4.77. Hence, today's PB Ratio of Acrivon Therapeutics is 1.53.

During the past 4 years, the highest P/B Ratio of Acrivon Therapeutics was 2.14. The lowest was 0.00. And the median was 0.00.

Acrivon Therapeutics Book Value per Share Historical Data

The historical data trend for Acrivon Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrivon Therapeutics Book Value per Share Chart

Acrivon Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Book Value per Share

-0.65

-1.84

7.78

5.38

Acrivon Therapeutics Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Book Value per Share	Get a 7-Day Free Trial								7.32	6.76	6.25	5.38	4.77

Competitive Comparison of Acrivon Therapeutics's Book Value per Share

For the Biotechnology subindustry, Acrivon Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acrivon Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acrivon Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Acrivon Therapeutics's PB Ratio falls into.

Acrivon Therapeutics Book Value per Share Calculation

Acrivon Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(121.20	-	0.00)	/	22.52
	=	5.38

Acrivon Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(107.98	-	0.00)	/	22.64
	=	4.77

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Acrivon Therapeutics (NAS:ACRV) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Acrivon Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Acrivon Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Acrivon Therapeutics (Acrivon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrivon Therapeutics Inc (NAS:ACRV) » Definitions » Book Value per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Arsenal Way, Suite 100, Watertown, MA, USA, 02472

Website

https://www.acrivon.com

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Executives

Mary Miller	officer: Chief Legal Officer	C/O BUTTERFLY NETWORK, INC., 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Peter Blume-jensen	director, officer: President and CEO	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Chione Ltd	10 percent owner	SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101, 6015, LARNACA G4 CY
Charles M Baum	director	C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Rasmus Holm-jorgensen	officer: Chief Financial Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Eric Devroe	officer: Chief Operating Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Anastasis Nikolaou	10 percent owner	C/O CHIONE LTD/ SIMOU MENARDOU 5, KIFISIA COURT,OFFICE 225, LARNACA G4 6015
Michael John Tomsicek	director	28 OVERLOOK DRIVE, BEDFORD MA 01730
Erick Gamelin	officer: Chief Medical Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Kristina Masson	director, officer: EVP - Business Operations	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Ra Capital Nexus Fund Ii, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116